Engineering and Design of Chimeric Antigen Receptors

Overview

Journal Mol Ther Methods Clin Dev

Publisher Cell Press

Date 2019 Jan 23

PMID 30666307

Citations 220

Authors

Sonia Guedan

Hugo Calderon

Avery D Posey Jr

Marcela V Maus

Affiliations

Soon will be listed here.

Abstract

T cells engineered with chimeric antigen receptors (CARs) have emerged as a potent new class of therapeutics for cancer, based on their remarkable potency in blood cancers. Since the first clinical reports of their efficacy emerged 7 years ago, investigators have focused on the mechanisms and properties that make CARs effective or toxic, and their effects on T cell biology. Novel CAR designs coupled with improvements in gene transfer technology, incorporating advances in gene editing, have the potential to increase access to engineered cell therapies, as well as improve their potency in solid tumors.

Citing Articles

A chimeric antigen receptor tailored to integrate complementary activation signals potentiates the antitumor activity of NK cells.

Yi E, Lee E, Park H, Lee H, Yun S, Kim H J Exp Clin Cancer Res. 2025; 44(1):86.

PMID: 40045373 PMC: 11884141. DOI: 10.1186/s13046-025-03351-5.

Exploring CAR-PBMCs: A Novel Strategy Against EGFR-Positive Tumor Cells.

Tirziu A, Gavriliuc O, Bojin M, Paunescu V Biomedicines. 2025; 13(2).

PMID: 40002679 PMC: 11853248. DOI: 10.3390/biomedicines13020264.

Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy.

De Lucia A, Mazzotti L, Gaimari A, Zurlo M, Maltoni R, Cerchione C Front Immunol. 2025; 16:1515748.

PMID: 39995659 PMC: 11847692. DOI: 10.3389/fimmu.2025.1515748.

Empowering Natural Killer Cells to Combat Acute Myeloid Leukemia: Perspective on CAR-NK Cell Therapy.

Gierschek F, Schlueter J, Kuhnel I, Feigl F, Schmiedel D, Prufer M Transfus Med Hemother. 2025; 52(1):42-60.

PMID: 39944413 PMC: 11813277. DOI: 10.1159/000540962.

CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity.

Kong Y, Li J, Zhao X, Wu Y, Chen L Front Immunol. 2025; 15():1519671.

PMID: 39850899 PMC: 11754230. DOI: 10.3389/fimmu.2024.1519671.

References

Dalziel M, Whitehouse C, McFarlane I, Brockhausen I, Gschmeissner S, Schwientek T . The relative activities of the C2GnT1 and ST3Gal-I glycosyltransferases determine O-glycan structure and expression of a tumor-associated epitope on MUC1. J Biol Chem. 2000; 276(14):11007-15. DOI: 10.1074/jbc.M006523200. View

Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E . A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2003; 348(3):255-6. DOI: 10.1056/NEJM200301163480314. View

Hacein-Bey-Abina S, von Kalle C, Schmidt M, McCormack M, Wulffraat N, Leboulch P . LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003; 302(5644):415-9. DOI: 10.1126/science.1088547. View

Imai C, Mihara K, Andreansky M, Nicholson I, Pui C, Geiger T . Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia. 2004; 18(4):676-84. DOI: 10.1038/sj.leu.2403302. View

Chmielewski M, Hombach A, Heuser C, Adams G, Abken H . T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. J Immunol. 2004; 173(12):7647-53. DOI: 10.4049/jimmunol.173.12.7647. View

Watts T . TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol. 2005; 23:23-68. DOI: 10.1146/annurev.immunol.23.021704.115839. View

Guest R, Hawkins R, Kirillova N, Cheadle E, Arnold J, ONeill A . The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J Immunother. 2005; 28(3):203-11. DOI: 10.1097/01.cji.0000161397.96582.59. View

Pule M, Straathof K, Dotti G, Heslop H, Rooney C, Brenner M . A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther. 2005; 12(5):933-41. DOI: 10.1016/j.ymthe.2005.04.016. View

Hendriks J, Xiao Y, Rossen J, van der Sluijs K, Sugamura K, Ishii N . During viral infection of the respiratory tract, CD27, 4-1BB, and OX40 collectively determine formation of CD8+ memory T cells and their capacity for secondary expansion. J Immunol. 2005; 175(3):1665-76. DOI: 10.4049/jimmunol.175.3.1665. View

10.

Ding S, Wu X, Li G, Han M, Zhuang Y, Xu T . Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice. Cell. 2005; 122(3):473-83. DOI: 10.1016/j.cell.2005.07.013. View

11.

Lamers C, Sleijfer S, Vulto A, Kruit W, Kliffen M, Debets R . Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol. 2006; 24(13):e20-2. DOI: 10.1200/JCO.2006.05.9964. View

12.

Balciunas D, Wangensteen K, Wilber A, Bell J, Geurts A, Sivasubbu S . Harnessing a high cargo-capacity transposon for genetic applications in vertebrates. PLoS Genet. 2006; 2(11):e169. PMC: 1635535. DOI: 10.1371/journal.pgen.0020169. View

13.

Wilkie S, Picco G, Foster J, Davies D, Julien S, Cooper L . Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J Immunol. 2008; 180(7):4901-9. DOI: 10.4049/jimmunol.180.7.4901. View

14.

Singh H, Manuri P, Olivares S, Dara N, Dawson M, Huls H . Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res. 2008; 68(8):2961-71. PMC: 2424272. DOI: 10.1158/0008-5472.CAN-07-5600. View

15.

James S, Greenberg P, Jensen M, Lin Y, Wang J, Till B . Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J Immunol. 2008; 180(10):7028-38. PMC: 2585549. DOI: 10.4049/jimmunol.180.10.7028. View

16.

Fos C, Salles A, Lang V, Carrette F, Audebert S, Pastor S . ICOS ligation recruits the p50alpha PI3K regulatory subunit to the immunological synapse. J Immunol. 2008; 181(3):1969-77. DOI: 10.4049/jimmunol.181.3.1969. View

17.

Carpenito C, Milone M, Hassan R, Simonet J, Lakhal M, Suhoski M . Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A. 2009; 106(9):3360-5. PMC: 2651342. DOI: 10.1073/pnas.0813101106. View

18.

Milone M, Fish J, Carpenito C, Carroll R, Binder G, Teachey D . Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009; 17(8):1453-64. PMC: 2805264. DOI: 10.1038/mt.2009.83. View

19.

Mates L, Chuah M, Belay E, Jerchow B, Manoj N, Acosta-Sanchez A . Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet. 2009; 41(6):753-61. DOI: 10.1038/ng.343. View

20.

Kochenderfer J, Feldman S, Zhao Y, Xu H, Black M, Morgan R . Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother. 2009; 32(7):689-702. PMC: 2747302. DOI: 10.1097/CJI.0b013e3181ac6138. View